DICE Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
DICE Therapeutics, a biopharmaceutical firm, announced participation in the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 12:00 p.m. PST/3:00 p.m. EST. The event will showcase DICE's innovative oral therapeutic candidates targeting chronic diseases in immunology. Utilizing its DELSCAPE platform, DICE aims to develop selective oral small molecules to rival systemic biologics in effectiveness. Their lead candidates focus on IL-17, addressing critical immunology indications.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced management will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 12:00 p.m. PST / 3:00 p.m. EST.
A live and archived webcast of the presentation will be accessible under “News & Events” in the Investors section of the company's website for 90 days after the event.
About DICE Therapeutics, Inc.
DICE Therapeutics, Inc. is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. The Company’s DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. DICE’s lead therapeutic candidates are oral antagonists of the pro-inflammatory signaling molecule, IL-17, which is a validated drug target implicated in a variety of immunology indications. DICE is also developing oral therapeutic candidates targeting α4ß7 integrin and αVß1/αVß6 integrin for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.
Contacts:
Media:
Katie Engleman, 1AB
katie@1abmedia.com
Investors:
investors@dicetx.com
FAQ
What is DICE Therapeutics presenting at the J.P. Morgan Healthcare Conference?
When is DICE Therapeutics' presentation at the J.P. Morgan Healthcare Conference?
How can I access DICE Therapeutics' conference presentation?
What is the focus of DICE Therapeutics' research?
What technology does DICE Therapeutics utilize for drug development?
